National Quality Improvement Conference

Discontinued Medications: Are they really discontinued?

Leo Qian Wen Jade¹, Toh Hsiao Peng¹, Jonathan Goh², Joyce Ang³, Tan Khim Hee¹, Megan Hey³, Rion Kudo¹ ¹ACSN, ²Respiratory Department, ³Inpatient wards **Ieo.qian.wen@skh.com.sg**



Problem Statement

Chronic Obstructive Pulmonary Disease (COPD) or asthma patients often come to the emergency department when they have an acute exacerbation. Due to concerns of aerosolization of Covid-19, wet nebulizers were switched to dry nebulizers (Ipratropium with salbutamol).

Potential Solutions

A root cause analysis was performed and identified the lack of knowledge from both patients and healthcare workers as a key contributor to the problem. To address this, PDSA cycle 1 and 2 were conducted.

PDSA Cycle 1


Patients were counselled on the

These inhalers are commonly issued inpatient and bought home by patients upon discharge. However, ipratropium inhalers should not be used by patients at home, unless ordered by doctors. Patients might be unaware and continue to administer ipratropium after discharge resulting in adverse side effects.

Project Aim

To reduce the incidence of patients inappropriately discharged with ipratropium by 80% within 6 months.

Lessons Learnt




PDSA Cycle 2

Workshops was conducted to educate nurses from medical wards on the appropriate use of ipratropium and side effects from excessive use to ensure that nurses understands the importance of discontinuing ipratropium if not required on discharge.


indications of ipratropium and to stop administration post-discharge

Ward nurses were informed to discard ipratropium upon discharge

Doctors were informed to discontinue ipratropium inhalers on discharge



Outcomes & Impacts



There were some difficulties in collaborating with various stakeholders. Fortunately, stakeholders were kept updated by the leader after meetings which ensured that everyone were on the same page.

Interpretating the data collected was another challenge faced which was overcame by consulting colleagues to assist in the data analysis. Brought home ipratropium
Did not bring home
Percentage
Target

Chart 1: Monthly rate of patients who brought and did not bring home ipratropium

Before intervention in Oct 22, only 5% of patients did not bring home ipratropium and up to 46% of patients continued to use ipratropium post-discharge. Postintervention, **84% of patient did not bring home ipratropium.**

The respiratory nurse-led interventions and workshops have reflected a significant change in practice. With ongoing respiratory workshops and reinforcement, the incidences of patients inappropriately discharged with ipratropium will be further reduced, minimizing the risk of unintended side effects.